Taysha Gene Therapies, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | -$0.11 | -$0.11 | -$0.11 |
| Q2 2024 | 2 | -$0.16 | -$0.16 | -$0.16 |
| Q3 2024 | 6 | -$0.10 | -$0.09 | -$0.09 |
| Q4 2024 | 2 | -$0.08 | -$0.08 | -$0.08 |
| Q1 2025 | 5 | -$0.10 | -$0.10 | -$0.10 |
| Q2 2025 | 5 | -$0.10 | -$0.10 | -$0.10 |
| Q3 2025 | 5 | -$0.09 | -$0.09 | -$0.09 |
| Q4 2025 | 5 | -$0.10 | -$0.10 | -$0.10 |
| Q1 2026 | 2 | -$0.09 | -$0.09 | -$0.09 |
| Q2 2026 | 2 | -$0.09 | -$0.09 | -$0.09 |
| Q3 2026 | 2 | -$0.09 | -$0.09 | -$0.09 |
| Q4 2026 | 2 | -$0.09 | -$0.09 | -$0.09 |
Taysha Gene Therapies, Inc. Earnings Date And Information
Taysha Gene Therapies, Inc. last posted its earnings results on Monday, August 12th, 2024. The company reported $-0.09 earnings per share for the quarter, topping analysts' consensus estimates of $-0.1 by $0.01. The company had revenue of 1.11 M for the quarter and had revenue of 15.45 M for the year. Taysha Gene Therapies, Inc. has generated $-1 earnings per share over the last year ($-0.96 diluted earnings per share) and currently has a price-to-earnings ratio of -2.59. Taysha Gene Therapies, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 12th, 2024 based on prior year's report dates.
Taysha Gene Therapies, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/12/2024 | Q2 2024 | -$0.10 | -$0.09 | 0.01 | $2.76 M | $1.11 M |
| 05/14/2024 | Q1 2024 | -$0.11 | -$0.10 | 0.01 | $3.41 M | |
| 03/19/2024 | Q4 2023 | -$0.09 | $0.26 | 0.35 | $3.60 M | |
| 11/14/2023 | Q3 2023 | -$0.13 | -$0.93 | -0.8 | $2.33 M | $4.75 M |
| 08/14/2023 | Q2 2023 | -$0.31 | -$0.38 | -0.07 | $2.40 M | $2.40 M |
| 05/11/2023 | Q1 2023 | -$0.39 | -$0.32 | 0.07 | $4.71 M | |
| 04/27/2023 | Q4 2022 | -$1.03 | $2.50 M | |||
| 11/08/2022 | Q3 2022 | -$0.89 | -$0.67 | 0.22 | $0 | |
| 08/11/2022 | Q2 2022 | -$1.05 | -$0.87 | 0.18 | $0 | |
| 05/16/2022 | Q1 2022 | -$1.04 | -$1.33 | -0.29 | $0 | |
| 03/31/2022 | Q4 2021 | -$1.21 | -$1.32 | -0.11 | $0 | |
| 11/10/2021 | Q3 2021 | -$1.02 | -$1.35 | -0.33 | $0 | |
| 08/16/2021 | Q2 2021 | -$0.81 | -$1.09 | -0.28 | $0 | |
| 05/11/2021 | Q1 2021 | -$0.54 | -$0.87 | -0.33 | $0 | |
| 03/03/2021 | Q4 2020 | -$0.37 | -$1.04 | -0.67 | $0 | |
| 11/12/2020 | Q3 2020 | -$0.17 | -$1.28 | -1.11 | $0 | |
| 06/30/2020 | Q2 2020 | -$0.61 | $0 | |||
| 03/31/2020 | Q1 2020 | -$0.36 | $0 | |||
| 12/31/2019 | Q4 2019 | -$0.07 | $0 |
Taysha Gene Therapies, Inc. Earnings: Frequently Asked Questions
-
When is Taysha Gene Therapies, Inc.'s earnings date?
Taysha Gene Therapies, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 12th, 2024 based off last year's report dates.
-
Did Taysha Gene Therapies, Inc. beat their earnings estimates last quarter?
In the previous quarter, Taysha Gene Therapies, Inc. (:TSHA) reported $-0.09 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.1 by $0.01.
-
How can I listen to Taysha Gene Therapies, Inc.'s earnings conference call?
The conference call for Taysha Gene Therapies, Inc.'s latest earnings report can be listened to online.
-
How can I read Taysha Gene Therapies, Inc.'s conference call transcript?
The conference call transcript for Taysha Gene Therapies, Inc.'s latest earnings report can be read online.
-
How much revenue does Taysha Gene Therapies, Inc. generate each year?
Taysha Gene Therapies, Inc. (:TSHA) has a recorded annual revenue of $15.45 M.
-
How much profit does Taysha Gene Therapies, Inc. generate each year?
Taysha Gene Therapies, Inc. (:TSHA) has a recorded net income of $15.45 M. Taysha Gene Therapies, Inc. has generated $-0.96 earnings per share over the last four quarters.
-
What is Taysha Gene Therapies, Inc.'s price-to-earnings ratio?
Taysha Gene Therapies, Inc. (:TSHA) has a price-to-earnings ratio of -2.59 and price/earnings-to-growth ratio is -0.1.
